CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
Aims: To assess prognostic value of pre-therapy carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) blood levels in non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICIs) and their early change as predictor of benefit. Materials and methods:...
Zapisane w:
| Główni autorzy: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
SAGE Publishing
2020-10-01
|
| Seria: | Therapeutic Advances in Medical Oncology |
| Dostęp online: | https://doi.org/10.1177/1758835920952994 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|